Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...

“My life is unfortunately never going to be what it was,” said Emily McAllister ...

This article is part of Nature Outlook: Skin, an editorially independent supplement produced with financial support from LEO Pharma. About this content. KaDee Troop is the mother of seven adopted ...

Please provide your email address to receive an email when new articles are posted on . The researchers were tasked with helping a patient who had a novel form of recalcitrant erythroderma. Using a ...

Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...

Transthyretin amyloidosis (ATTR) is a rare, progressive and highly aggressive degenerative disease. It is caused by the ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board. The independent data monitoring committee assessing a ...

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...

SALT LAKE CITY (ABC4) — A Utah woman is sharing her story after she survived an incredibly rare and often fatal skin disorder caused by an allergic reaction to antibiotics. Brandi Nicole Pond, who ...

Palvella Therapeutics, Inc. ( (PVLA)) has released its Q3 earnings. Here is a breakdown of the information Palvella Therapeutics, Inc. presented to its investors. Palvella Therapeutics, Inc. is a ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...